Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6403193 | 0.78 | PDK2 (0.41) | PDK2DRD2DRD3ESR1ESR2 | |
| SCHEMBL6401340 | 0.78 | PDK2 (0.41) | PDK2DRD2DRD3ESR1ESR2 | |
| SCHEMBL6403380 | 0.78 | PDK2 (0.41) | PDK2DRD2DRD3ESR1ESR2 | |
| SCHEMBL7983126 | 0.76 | SIGMAR1 (0.45) | — | |
| SCHEMBL7985550 | 0.76 | SIGMAR1 (0.45) | — | |
| SCHEMBL6400509 | 0.76 | PDK2 (0.43) | PDK2DRD2DRD3ESR1ESR2 | |
| SCHEMBL6406622 | 0.76 | PDK2 (0.43) | PDK2DRD2DRD3ESR1ESR2 | |
| SCHEMBL6400531 | 0.76 | PDK2 (0.43) | PDK2DRD2DRD3ESR1ESR2 | |
| SCHEMBL6585105 | 0.74 | ALDH1A1 (0.41) | PDK2DRD2DRD3ESR1ESR2 | |
| SCHEMBL17591321 | 0.71 | PDK2 (0.42) | PDK2DRD2DRD3ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1095939-B1 | Process for the preparation of piperidinylaminomethyl trifluoromethyl cyclic ether compounds | PFIZER PROD INC (US) | 2004-01-07 | — | — | EP | disclosed |
| US-20030236268-A1 | Process for the preparation of piperidinylaminomethyl trifluoromethyl cyclic ether compounds | CARON STEPHANIE (US) | 2003-12-25 | — | — | US | disclosed |
| US-6486325-B1 | Process for the preparation of piperidinylaminomethyl trifluoromethyl cyclic ether compounds | PFIZER INC | 2002-11-26 | — | — | US | disclosed |
| EP-1095939-A2 | Process for the preparation of piperidinylaminomethyl trifluoromethyl cyclic ether compounds | Pfizer Products Inc. (US) | 2001-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236268-A1 | Process for the preparation of piperidinylaminomethyl trifluoromethyl cyclic ether compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP1B1, PAICS | PDK2 3245/4885DRD2 1182/4885DRD3 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.